Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
Summary not available.
IGC Pharma (NYSE American: IGC) will showcase its Alzheimer’s-focused AI portfolio in seven presentations at AAIC 2026, July 12-15 in London.
Highlights include the AHA agentic harmonization platform, which cut a representative 100-variable data workflow from 28 to 2.5 hours, and updates on the Phase 2 CALMA trial of IGC-AD1.
IGC Pharma (NYSE American: IGC) announced that CEO Ram Mukunda and Principal Financial Officer Claudia Grimaldi acquired a combined 4,274,853 common shares at $0.27 per share directly from the company.
The transaction canceled about $1.15 million in amounts owed to them, reduced obligations with no cash outlay, and increased management’s direct common equity ownership in a restricted private placement approved by independent directors.
IGC Pharma (NYSE American: IGC) launched the beta of its Agentic Harmonization Assistant (AHA), an AI-driven platform to harmonize fragmented Alzheimer's and aging datasets. In an internal 100-variable workflow, AHA cut harmonization time from 28 hours to 2.5 hours, a reported 90% reduction including human verification.
AHA uses a patent-pending multi-agent architecture and is being extended to imaging (MRI, PET, CT) and omics data. AHA is slated for demonstration at AAIC 2026 in London. IGC’s Phase 2 CALMA trial of IGC-AD1 has reached 100% baseline randomization and is moving toward follow-up and topline analysis.
IGC Pharma (NYSE American:IGC) reported that its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's dementia has reached the planned 146-patient enrollment, with all participants randomized at baseline.
The company will allow limited over-enrollment to offset attrition and support robust modified intent-to-treat, end-of-treatment, and exploratory analyses ahead of database lock and topline results.
IGC Pharma (NYSE American: IGC)/b) announced that Ascendiant Capital Markets raised its price target to
The report, focused on clinical progress and potential 2026 catalysts, centers on IGC-AD1, now in the Phase 2 CALMA trial for agitation in Alzheimer’s disease.
IGC Pharma (NYSE American: IGC) added the Icahn School of Medicine at Mount Sinai in New York as a clinical site in its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer's disease. About 80% of targeted participants have completed participation, and the study is progressing toward database lock and topline analysis.
IGC Pharma (NYSE American: IGC) reported Q1 2026 results and progress on its Alzheimer’s programs. The Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s remains ongoing, with about 80% of the 146-patient target enrolled after March 2026 and additional U.S. trial sites activated.
IGC filed utility patent applications for its AHA AI-based data harmonization system and received a Canadian Notice of Allowance covering IGC-AD1’s composition. Q1 2026 revenue was $317,000, R&D $1.3 million, SG&A $1.2 million, and net loss attributable to shareholders $2.4 million. Debt totaled $917,000 at March 31, 2026, with an extra $585,000 debt raised afterward and access to an undrawn $12 million credit facility.
IGC Pharma (NYSE American: IGC) will present new Tau-PET biomarker research at the 2026 Global Tau Conference in Washington, D.C., May 14-15, 2026.
The study uses Shannon entropy on Tau-PET data from 931 participants to assess tau spreading patterns, cognition, and potential use in Alzheimer's monitoring and patient stratification.
IGC Pharma (NYSE American: IGC) reported participation in the caregiver podcast Autumn Is Here to raise awareness of agitation in Alzheimer's and support patient engagement in its Phase 2 CALMA trial. The company said CALMA has reached approximately 80% enrollment and is advancing toward completion.
The episode featured IGC staff discussing recognition of agitation, differences from other behavioral symptoms, and the role of caregiver education in improving clinical-trial participation.